Technical Analysis for COGT - Cogent Biosciences, Inc.

Grade Last Price % Change Price Change
F 9.80 -0.10% -0.01
COGT closed down 0.1 percent on Thursday, September 28, 2023, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Low Weakness -0.10%
Wide Bands Range Expansion -0.10%
Oversold Stochastic Weakness -0.10%
New 52 Week Closing Low Bearish 1.14%
Slingshot Bearish Bearish Swing Setup 1.14%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 9 hours ago
Possible NR7 about 11 hours ago
Possible Inside Day about 11 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Down 2 % about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Advanced Gastrointestinal Stromal Tumors Gastrointestinal Stromal Tumors

Is COGT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 15.68
52 Week Low 9.48
Average Volume 746,869
200-Day Moving Average 12.01
50-Day Moving Average 11.78
20-Day Moving Average 11.26
10-Day Moving Average 10.27
Average True Range 0.51
RSI (14) 30.07
ADX 31.63
+DI 10.30
-DI 33.88
Chandelier Exit (Long, 3 ATRs) 11.71
Chandelier Exit (Short, 3 ATRs) 11.00
Upper Bollinger Bands 13.51
Lower Bollinger Band 9.02
Percent B (%b) 0.17
BandWidth 39.82
MACD Line -0.64
MACD Signal Line -0.46
MACD Histogram -0.1759
Fundamentals Value
Market Cap 190.19 Million
Num Shares 19.4 Million
Price-to-Sales 3.49
Price-to-Book 6.51
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.18
Resistance 3 (R3) 10.13 9.97 10.11
Resistance 2 (R2) 9.97 9.87 9.99 10.09
Resistance 1 (R1) 9.88 9.81 9.93 9.93 10.07
Pivot Point 9.72 9.72 9.74 9.74 9.72
Support 1 (S1) 9.63 9.62 9.68 9.68 9.53
Support 2 (S2) 9.47 9.56 9.49 9.51
Support 3 (S3) 9.38 9.47 9.49
Support 4 (S4) 9.43